Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.